These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28376267)

  • 1. Brain iron accumulation in Wilson's disease: A longitudinal imaging case study during anticopper treatment using 7.0T MRI and transcranial sonography.
    Dusek P; Skoloudik D; Maskova J; Huelnhagen T; Bruha R; Zahorakova D; Niendorf T; Ruzicka E; Schneider SA; Wuerfel J
    J Magn Reson Imaging; 2018 Jan; 47(1):282-285. PubMed ID: 28376267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilson's disease.
    Berger B; Mader I; Damjanovic K; Niesen WD; Stich O
    Clin Neurol Neurosurg; 2014 Dec; 127():122-4. PubMed ID: 25459257
    [No Abstract]   [Full Text] [Related]  

  • 3. Iron accumulation in the liver of male patients with Wilson's disease.
    Shiono Y; Wakusawa S; Hayashi H; Takikawa T; Yano M; Okada T; Mabuchi H; Kono S; Miyajima H
    Am J Gastroenterol; 2001 Nov; 96(11):3147-51. PubMed ID: 11721763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
    Hanukoglu A; Curiel B; Berkowitz D; Levine A; Sack J; Lorberboym M
    J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathogenesis and treatment of Wilson's disease].
    Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
    Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of penicillamine and zinc on iron metabolism in Wilson's disease.
    Medici V; Di Leo V; Lamboglia F; Bowlus CL; Tseng SC; D'Incà R; Irato P; Burra P; Martines D; Sturniolo GC
    Scand J Gastroenterol; 2007 Dec; 42(12):1495-500. PubMed ID: 17994470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease.
    Lozano Herrero J; Muñoz Bertrán E; Ortega González I; Gómez Espín R; López Espín MI
    Gastroenterol Hepatol; 2012 Dec; 35(10):704-7. PubMed ID: 22609346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
    Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
    Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penicillamine: the treatment of first choice for patients with Wilson's disease.
    Walshe JM
    Mov Disord; 1999 Jul; 14(4):545-50. PubMed ID: 10435489
    [No Abstract]   [Full Text] [Related]  

  • 10. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
    Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
    Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.
    Walshe JM
    Q J Med; 1973 Jul; 42(167):441-52. PubMed ID: 4728043
    [No Abstract]   [Full Text] [Related]  

  • 12. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
    Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
    Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penicillamine should not be used as initial therapy in Wilson's disease.
    Brewer GJ
    Mov Disord; 1999 Jul; 14(4):551-4. PubMed ID: 10435490
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient with late-onset Wilson's disease: deterioration with penicillamine.
    Sohtaoglu M; Ergin H; Ozekmekçi S; Gökdemir S; Sonsuz A; Arici C
    Mov Disord; 2007 Jan; 22(2):290-1. PubMed ID: 17083099
    [No Abstract]   [Full Text] [Related]  

  • 15. MRI and transcranial sonography findings in Wilson's disease.
    Martínez-Fernández R; Caballol N; Gómez-Choco M
    Mov Disord; 2013 Jun; 28(6):740. PubMed ID: 23712499
    [No Abstract]   [Full Text] [Related]  

  • 16. Wilson's disease.
    Ala A; Walker AP; Ashkan K; Dooley JS; Schilsky ML
    Lancet; 2007 Feb; 369(9559):397-408. PubMed ID: 17276780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penicillamine induced pseudo-pseudoxanthoma elasticum in a patient with Wilson's disease, which role plays the hepatologist?
    Ibáñez-Samaniego L; Ochoa-Palominos A; Catalina-Rodríguez MV; Salcedo-Plaza M; Clemente-Ricote G
    Rev Esp Enferm Dig; 2015 Mar; 107(3):190-1. PubMed ID: 25733050
    [No Abstract]   [Full Text] [Related]  

  • 19. Brief observations on the management of Wilson's disease.
    Walshe JM
    Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):1-3. PubMed ID: 122651
    [No Abstract]   [Full Text] [Related]  

  • 20. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.